SFDA expedited review programs: Impact on innovative oncology drug approvals

Key Takeaways

• High pathway adoption: 52.17% of SFDA drug approvals use expedited pathways—Priority Review, Breakthrough Designation, Verification/Abridged, or Conditional Approval—per SFDA Regulatory Framework Version 6.4.
• Priority Review timeline: The SFDA Priority Review Pathway delivers a 40% reduction in review time compared to standard regulatory assessments for qualifying oncology drugs.
• Global first approvals: Anktiva received conditional SFDA approval in January 2026 as the first regulatory authority globally to approve this interleukin-15 receptor agonist for metastatic non-small cell lung cancer (NSCLC).
• Breakthrough momentum: Imlunestrant secured Breakthrough Designation from the SFDA for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations.
• Market positioning: Early SFDA approvals allow pharmaceutical companies to establish clinical presence in Saudi Arabia while regulatory reviews continue in other major markets.

What SFDA Expedited Review Programs Exist?

The Saudi Food and Drug Authority serves as the national regulatory body overseeing pharmaceutical, biologic, and medical device approvals in Saudi Arabia. The SFDA maintains several expedited review pathways designed to accelerate patient access to innovative treatments for serious conditions, particularly in oncology.

The SFDA Regulatory Framework Version 6.4, published in June 2024, defines four primary expedited pathways:

Pathway	Description	Timeline Benefit
Priority Review	For drugs offering significant therapeutic advantage over existing treatments	40% reduction vs. regular review
Breakthrough Designation	For therapies with preliminary evidence of substantial improvement	Intensive guidance, rolling submissions
Verification/Abridged	For drugs with prior approval from recognized regulators (FDA, EMA)	Accelerated assessment
Conditional Approval	Market authorization based on preliminary data with post-approval commitments	Earlier market access

The Priority Review Pathway provides a 40% reduction in review timeline compared to the Regular Review Pathway, according to SFDA documentation. This mechanism applies to drugs addressing serious conditions that offer meaningful therapeutic advantages.

How Do Oncology Drugs Qualify for Expedited Review?

To qualify for SFDA expedited review, oncology drugs must demonstrate specific criteria. The drug should address a serious, life-threatening condition. It must provide preliminary evidence of significant clinical benefit over existing therapies. The treatment should fill an important therapeutic gap. Finally, it must meet an unmet medical need in the Saudi population.

The SFDA evaluates submitted data—including preclinical studies, early-phase clinical trials, and comparative efficacy evidence—to determine eligibility. Priority Review designation applies to drugs offering meaningful therapeutic advantages. The SFDA commits to expedited assessment timelines once granted.

Breakthrough Designation requires preliminary clinical evidence showing superiority over available alternatives. The SFDA provides intensive guidance to sponsors and may allow rolling submissions to expedite review durations. This designation helps accelerate development of promising therapies for patients with limited treatment options.

Verification and Abridged Pathways use prior regulatory approvals or established pharmacological data. The SFDA can rely on evidence packages from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or other recognized authorities to support accelerated assessments. This reduces redundant data generation and speeds market access for drugs already approved internationally.

Which Oncology Drugs Have Secured Expedited SFDA Approval?

Two notable examples demonstrate how SFDA expedited pathways work in practice: Anktiva and Imlunestrant.

Anktiva: First Global Approval for NSCLC

On January 14, 2026, the SFDA granted conditional approval for Anktiva (nogapendekin alfa inbakicept). This made the SFDA the first regulatory authority globally to approve this medication for metastatic non-small cell lung cancer (NSCLC). The approval covers use in combination with immune checkpoint inhibitors for adult patients whose disease progressed after standard-of-care therapy.

Anktiva works through a novel mechanism as an interleukin-15 (IL-15) receptor agonist. It binds to the IL-15 receptor, resulting in proliferation and activation of natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells—without proliferation of immuno-suppressive Treg cells.

The NSCLC approval was based on results from a single-arm clinical trial in patients who had not responded to one or more prior therapies, including immune checkpoint inhibitors. The study demonstrated potential improvement in survival. The SFDA granted conditional approval requiring a confirmatory trial to demonstrate long-term clinical benefit.

The SFDA also approved Anktiva for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ. Clinical trial results showed a complete response rate of 62%, which served as the primary endpoint for this indication.

Imlunestrant: Breakthrough Designation for Breast Cancer

The SFDA granted Breakthrough Designation to Imlunestrant (brand name Inluriyo) for advanced breast cancer. This selective estrogen receptor inhibitor antagonizes and degrades both wild-type and mutant ERα, inhibiting estrogen receptor-dependent gene transcription and cellular proliferation in ER-positive breast cancer cells.

The designation was based on clinical data from a global trial demonstrating improvement in progression-free survival compared to standard treatment in patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who had previously received endocrine therapy.

Per FDA prescribing information dated 2025, Imlunestrant subsequently received U.S. approval for the same indication at a recommended dosage of 400 mg orally once daily.

What Market Impact Do Expedited Approvals Create?

The prevalence of SFDA expedited approvals changes competitive dynamics in Saudi Arabia's pharmaceutical market. Oncology drug developers gain strategic advantage by entering the market early, establishing clinical presence ahead of competitors navigating standard regulatory timelines elsewhere.

Early SFDA approval creates unique market positioning. Companies can promote treatments to Saudi oncologists and healthcare systems while parallel regulatory reviews continue in Europe, the United States, and other regions. This temporal advantage enables brand establishment, physician familiarity, and accelerated patient access within the Saudi market.

The expedited approval framework shapes pharmaceutical investment priorities. Companies targeting Middle East market entry may prioritize SFDA submissions, potentially shifting resources to Saudi regulatory submissions earlier in product development cycles. This reflects growing recognition of the Middle East as an essential market for innovative oncology treatments.

How Does Expedited Review Affect Patient Access?

From a patient care perspective, SFDA expedited approvals significantly impact access to innovative cancer treatments. Saudi patients gain earlier access to drugs like Anktiva through accelerated regulatory pathways, potentially improving clinical outcomes compared to scenarios with prolonged regulatory delays.

The 52.17% adoption rate of expedited pathways indicates the SFDA maintains rigorous scientific standards while facilitating faster market access. Expedited designation does not compromise safety or efficacy requirements. Instead, it streamlines review processes, minimizes administrative delays, and prioritizes assessment of drugs addressing serious unmet needs.

Post-approval surveillance and conditional approval commitments ensure ongoing safety monitoring after rapid market entry. The SFDA applies consistent scientific rigor to expedited and standard reviews alike—faster timelines reflect process efficiency rather than reduced scrutiny.

Healthcare systems and oncologists in Saudi Arabia benefit from expanded treatment options. Early access to globally innovative drugs reduces treatment delays and aligns Saudi clinical practice with international oncology standards.

What Should Pharmaceutical Companies Consider?

For pharmaceutical companies developing oncology drugs, the SFDA expedited review framework offers strategic opportunities. Companies should assess SFDA pathway eligibility during early clinical development. Integrating Middle East market considerations into global strategies can optimize regulatory planning.

Engaging with SFDA regulatory specialists during preclinical and early-phase development can clarify pathway options. This early dialogue helps optimize submission packages for expedited review consideration.

Regulatory affairs professionals should monitor SFDA guidance documents and pathway updates. As the SFDA continues enhancing its expedited programs, refined eligibility criteria may create additional strategic avenues for oncology drug developers.

Healthcare policymakers in Saudi Arabia and the broader Middle East should view expedited approval frameworks as tools for improving patient access and fostering clinical innovation. Continued investment in SFDA regulatory capacity, scientific expertise, and post-approval surveillance infrastructure will maintain the credibility and effectiveness of these pathways.

Frequently Asked Questions

Primary Sources

1. Saudi Food and Drug Authority. Regulatory Framework for Drugs Approval, Version 6.4. Published June 11, 2024.
2. Saudi Food and Drug Authority. SFDA Approves Registration of "Anktiva" for the Treatment of Bladder and Lung Cancer. News release. January 16, 2026.
3. Saudi Food and Drug Authority. The SFDA Approves Breakthrough Designation Application for Breast Cancer Therapy "Inluriyo". News release.
4. U.S. Food and Drug Administration. INLURIYO (imlunestrant) Tablets: Highlights of Prescribing Information. FDA Label. 2025.
5. U.S. Securities and Exchange Commission. ImmunityBio, Inc. Form 8-K: Current Report. Filed January 14, 2026.

Related Profiles

• Anktiva (nogapendekin alfa inbakicept)
• Imlunestrant

Related Coverage

• SFDA Expedited Review Oncology: What You Need to Know
• Saudi Arabian Pharmaceutical Market: SFDA's Accelerated Drug Approvals Impact
• Anktiva Receives SFDA Accelerated Approval for Oncology Indications